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It is becoming clear that postnatal neovascularization in-
volves circulating endothelial progenitor cells (EPCs),
which home to sites of neovascularization and differentiate
into endothelial cells in a manner consistent with a process
initially termed “vasculogenesis” (1). These circulating
EPCs derive from hematopoietic stem cells and contribute
to reparative processes, including neovascularization after
ischemia (2,3). Ischemia, vascular trauma, and pro-
angiogenic chemokines stimulate EPC mobilization from
the bone marrow (4–6). In particular, ischemia was shown
to enhance circulating EPC levels by vascular endothelial
growth factor (VEGF)-mediated mobilization of bone
marrow-derived EPCs (5). Mobilized EPCs are then at-
tracted to ischemic areas by locally elevated VEGF or
stromal cell-derived factor-1 levels (7). The functional
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regeneration of ischemic tissue by improved neovascularization
and possibly tissue repair is critically dependent on the mobi-
lization and integration of EPCs into the ischemic tissue.
Moreover, infusions of EPCs expanded ex vivo can limit scar
extension in the ischemic myocardium (8) and improve the
recovery of contractility and thereby may be useful as a novel
therapeutic approach (9). However, aging may constitute a
potential limitation to the ability of progenitor cells to sustain
ischemic tissue neovascularization and repair.
Aging is one of the major risk factors for coronary artery
disease (CAD) and is associated with a reduction of the
functional activity of the endothelium (10). In an animal
model, aging also appeared to impair neovascularization after
ischemia (11). Moreover, increasing age was shown to be
associated with reduced levels of circulating EPCs in patients
with CAD (12), thereby providing first evidence of dysfunc-
tional regulation of EPCs in elderly individuals. Age may
interfere with neovascularization at various steps (Fig. 1).
Although basal hematopoiesis is maintained in aging, the
capacity of reacting to stress-induced mobilization gradually
declines with increased age (for a review see [13]). Thus, one
may speculate that elderly patients may show a limited re-
sponse toward EPC-mobilizing stimuli after critical ischemia.
Age may also interfere with the functional activity of
stem/progenitor cells. Edelberg et al. (14) previously demon-
strated that only transplantation of young bone marrow-
derived cells restored age-associated impaired neovasculariza-
tion, whereas bone marrow of aged mice was not effective.
Moreover, the migratory capacity of peripheral blood-derived
EPCs of elderly patients with CAD is significantly reduced
(12). Finally, age may interfere with the survival of circulating
stem/progenitor cells. An increased turnover rate in the pro-
genitor cell population with increased susceptibility to apopto-
sis may be due to an imbalance in pro- and anti-apoptotic
factors or a decline in the antioxidant defense, as suggested for
the aging process in general.
In this issue of the Journal, Scheubel et al. (15) provide
novel evidence that age leads to a reduction of VEGF,
which might limit mobilization and survival/differentiation
of EPCs. The authors report that the number of circulating
CD34/CD133 cells, which defines a subpopulation of
immature hematopoietic precursor cells, and VEGF levels
are reduced as a function of age in 50 patients (age 43 to 80
years) before undergoing coronary artery bypass graft sur-
gery (CABG). In this group of patients, the increase in
VEGF and EPC levels after CABG was consistently
depressed in older patients. This observation is supported by
previous experimental studies demonstrating a reduction of
VEGF levels during aging (16). Interestingly, in the present
study, other risk factors for CAD did not apparently explain
the observed differences, although other studies showed an
inverse correlation of CAD risk factors with EPC levels
(12,17). Also, the plasma levels of several other cytokines
and chemokines were not changed in this group of patients,
suggesting that systemically depressed VEGF levels may
play a crucial role in the reduction of EPC levels. However,
due to limitations inherent in the clinical scenario, the
causal role of VEGF cannot be assessed. Indeed, the
responsiveness in CABG-induced increases in EPC and
VEGF release is different in patients in the middle tertile
(62 to 69 years old). Thus, further experimental studies are
necessary to prove that the reduction of VEGF is indeed the
limiting factor for circulating EPC levels. Overall, the
authors conclude that although administration of EPCs
might expand the scope of therapies aimed at promoting
neovascularization and tissue regeneration, this may be
problematic in elderly patients. This study highlights a
potentially relevant feature of the endogenous repair process
in elderly patients and poses an interesting question on the
value of therapies based on expansion of endogenous EPCs
in elderly subjects.
An important question with respect to potential cell
therapeutic approaches is whether the endogenous EPC
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pool can be revitalized in vivo or after ex vivo expansion by
treatment with pharmacologic agents, cytokines, or even gene
therapy. Previous studies have shown that VEGF gene transfer
efficiently mobilizes EPCs in humans (18). Other possibilities
to augment circulating EPC levels in elderly patients may
include the use of statins, which have been shown to increase
EPC levels in patients with CAD (19). One may also consider
estrogens (20) or erythropoietin (21) as a possible strategy to
increase EPCs. Clearly, the susceptibility to these treatments in
elderly patients has not been tested.
Another option may be to more directly influence age-
associated changes in telomere biology ex vivo. Age leads to
telomere shortening and dysfunction, which are implicated
in senescence and apoptotic signaling. Counteracting the
reduction of telomere length by overexpression of the active
subunit of the telomerase, TERT, increased the neovascu-
larization capacity of EPCs from healthy volunteers (22).
Likewise, one may consider the use of the telomere repeat
binding factor, TRF2, which protects critically short telo-
meres from fusion and confers protection from oxidative
stress in other cell types (23,24).
Taken together, although it may still be premature to
rush to conclusions about the role of age-related phenomena
on EPC-based therapies, the findings reported by Scheubel
et al. (15) strengthen the idea that the EPC pool must be
stimulated in vivo and most likely expanded ex vivo to
enhance neovascularization and improve myocardial func-
tion. In light of the results of this study, these approaches
would be even more important in elderly individuals.
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Figure 1. Possible influences of age on endothelial progenitor levels.
VEGF  vascular endothelial growth factor.
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